Methyl aminolevulinate
Clinical data | |
---|---|
AHFS/Drugs.com | Multum Consumer Information |
ATC code | L01XD03 (WHO) |
Identifiers | |
| |
CAS Number | 33320-16-0 |
PubChem (CID) | 16052023 |
DrugBank | DB00992 |
ChemSpider | 13180320 |
ChEMBL | CHEMBL1096562 |
Chemical and physical data | |
Formula | C6H11NO3 |
Molar mass | 145.156 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Methyl aminolevulinate (MAL) is a drug used as a sensitizer in photodynamic therapy. It is a prodrug that is metabolized to protoporphyrin IX. It is marketed as Metvix.
Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser.
Metvix is developed by Photocure and Galderma has bought all rights to Metvix.[1]
Approvals and indications
Methyl aminolevulinate is approved in New Zealand for treatment of basal cell carcinoma.[2]
It is now approved in many countries and has been used to treat non-melanoma skin cancer (including basal cell carcinoma).[3]
It has some advantages over Levulan.[4]
It has been reported as controversial in some quarters, with severe pain allegedly being experienced by some patients. [5]
References
- ↑ http://photocure.com/NEWS/newcontainer/Photocure-divests-Metvix-to-Galderma-for-EUR-51-million/ Photocure divests Metvix to Galderma
- ↑ http://dermnetnz.org/procedures/metvix-pdt.html "Methyl aminolevulinate photodynamic therapy (MAL PDT)"
- ↑ http://www.medicalnewstoday.com/articles/36953.php "New 5 Year Metvix-PDT Data Demonstrate Long-Term Efficacy & Reliability For NM Skin Cancer Treatment" 2006
- ↑ http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_13/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009 by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
- ↑ http://www.abc.net.au/news/2013-11-16/concerns-raised-over-side-effects-of-skin-cancer-cream/5096496